KB-1102

Teprotumumab

12119

Background of Teprotumumab

Thyroid eye disease (TED) is a complex autoimmune condition that results in disfiguring orbital changes that may be associated with the development of diplopia and optic neuropathy. Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of this disease. Teprotumumab is a fully human monoclonal immunoglobulin G1 to IGF-1R that was recently approved for the treatment of TED in the USA. Binding of teprotumumab inhibits signaling through the IGF-R1/TSH-R complex and the downstream pathways.

Specifications

Catalog Number	KB-1102
Antibody Name	Teprotumumab
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	IGF1R
Species Reactivity	Human, Cyno
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA \| FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Wang Y, Patel A, Douglas RS. Thyroid eye disease: how a novel therapy may change the treatment paradigm. Ther Clin Risk Manag. 2019;15:1305–18.
Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748–61.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341–52.